About Dr. Sun Huichuan
Dr. Sun Huichuan (孙惠川) is a Professor, Doctoral Supervisor, and one of China's leading hepatic oncological surgeons, based at the Department of Hepatic Surgery, Fudan University Shanghai Cancer Center (FUSCC). With extensive clinical and research expertise in the surgical management of hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma, liver metastases, and other hepatic malignancies, Dr. Sun is recognized as a senior authority in hepatic oncological surgery at China's foremost dedicated cancer center. His clinical practice is defined by a commitment to oncological precision, maximal liver parenchyma preservation, and the integration of surgical resection with locoregional therapies — including TACE, ablation, and SBRT — and systemic therapy in comprehensive, multidisciplinary hepatic oncology management strategies.
Hepatocellular carcinoma is the most common primary liver cancer and one of the leading causes of cancer death worldwide, with China accounting for approximately half of all global HCC cases — a burden driven by the high prevalence of chronic hepatitis B infection in the Chinese population. Surgical resection remains the cornerstone of curative treatment for HCC, but the majority of patients present with disease that is not amenable to upfront resection due to tumor size, multifocality, vascular invasion, or underlying liver dysfunction. The optimal management of HCC — including the selection of patients for resection, the design of downstaging strategies for initially unresectable disease, and the integration of locoregional and systemic therapies — requires a level of hepatic oncology expertise and multidisciplinary coordination that is available at only a small number of specialized centers. Dr. Sun's clinical practice at FUSCC — supported by the center's comprehensive hepatic oncology multidisciplinary team — provides international patients with access to the most advanced hepatic oncological surgery and multimodal HCC management available in China.
Hospital Affiliation: Department of Hepatic Surgery, Fudan University Shanghai Cancer Center
Fudan University Shanghai Cancer Center (FUSCC) is China's foremost dedicated cancer center. Its Department of Hepatic Surgery is one of the highest-volume hepatic oncological surgery programs in China, performing a large number of hepatic resections annually for HCC, intrahepatic cholangiocarcinoma, and liver metastases. The department's hepatic oncology multidisciplinary team integrates hepatic surgery, interventional radiology (TACE, ablation), medical oncology, radiation oncology (SBRT), and hepatology for comprehensive HCC management. Its laparoscopic and robotic hepatic surgery program provides minimally invasive approaches to hepatic resection for appropriately selected patients, enabling shorter hospital stays, reduced blood loss, and faster recovery compared to open surgical approaches.
Clinical Specialties: What Dr. Sun Huichuan Treats
- Hepatocellular carcinoma (HCC) surgery — anatomical and non-anatomical hepatic resection for resectable HCC; laparoscopic and robotic hepatic resection for selected cases; major hepatectomy (right hepatectomy, left hepatectomy, extended hepatectomy) for large or centrally located HCC; repeat hepatic resection for recurrent HCC; portal vein embolization (PVE) for future liver remnant augmentation before major hepatectomy; associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) for small future liver remnant; vascular resection and reconstruction for HCC with portal vein or hepatic vein involvement
- Downstaging and conversion surgery for initially unresectable HCC — multidisciplinary assessment of resectability using BCLC and CNLC staging; downstaging strategies including TACE, hepatic arterial infusion chemotherapy (HAIC), SBRT, and systemic therapy (atezolizumab-bevacizumab, lenvatinib) for conversion to resectability; reassessment of resectability after downstaging; conversion hepatectomy after successful downstaging; coordination with interventional radiology and medical oncology for downstaging protocol design
- Intrahepatic cholangiocarcinoma (iCCA) surgery — hepatic resection with adequate margins for resectable iCCA; major hepatectomy with caudate lobe resection for centrally located iCCA; lymphadenectomy for nodal staging; coordination with medical oncology for adjuvant gemcitabine/cisplatin chemotherapy and targeted therapy for FGFR2 fusion-positive and IDH1-mutant iCCA
- Colorectal liver metastases (CRLM) surgery — synchronous and metachronous colorectal liver metastasis resection; two-stage hepatectomy for bilateral CRLM; PVE and ALPPS for small future liver remnant; repeat hepatic resection for recurrent CRLM; coordination with colorectal surgery and medical oncology for perioperative chemotherapy (FOLFOX, FOLFIRI, bevacizumab, cetuximab) and optimal sequencing of systemic therapy and surgery
- Other liver tumors — surgical resection of hepatic adenoma, focal nodular hyperplasia, and other benign hepatic tumors with uncertain diagnosis or symptomatic disease; resection of neuroendocrine tumor liver metastases; resection of non-colorectal, non-neuroendocrine liver metastases from breast cancer, gastric cancer, and other primaries in selected patients
- Locoregional therapy coordination — coordination with the interventional radiology team for TACE, drug-eluting bead TACE (DEB-TACE), and hepatic arterial infusion chemotherapy (HAIC) for unresectable HCC; coordination for thermal ablation (radiofrequency ablation, microwave ablation) for small HCC not amenable to resection; coordination with radiation oncology for SBRT for HCC and liver metastases; integration of locoregional and systemic therapies in comprehensive HCC management
- Perioperative management of hepatic surgery — preoperative liver function assessment using Child-Pugh score, MELD score, and indocyanine green (ICG) clearance test; future liver remnant volumetry by CT; management of portal hypertension and esophageal varices before hepatic surgery; antiviral therapy optimization for HBV-related HCC before and after surgery; postoperative liver failure prevention and management
Why International Patients Choose Dr. Sun Huichuan and FUSCC
International patients seek hepatic oncological surgery consultation with Dr. Sun Huichuan and FUSCC for reasons that reflect both the clinical depth of his hepatic surgery expertise and the comprehensive multidisciplinary HCC management infrastructure available at China's foremost cancer center.
For patients with HCC who have been told that their tumor is unresectable — due to size, multifocality, vascular proximity, or inadequate future liver remnant — Dr. Sun's expertise in downstaging strategies and conversion surgery provides a reassessment of resectability that frequently identifies a pathway to curative resection not previously considered. The availability of HAIC, TACE, SBRT, and the latest systemic therapy combinations (atezolizumab-bevacizumab, lenvatinib) for downstaging at FUSCC, combined with Dr. Sun's technical capability for major hepatectomy with vascular resection and reconstruction, means that patients who have been told their HCC is inoperable may find that curative resection is achievable after effective downstaging.
For patients with colorectal liver metastases requiring complex two-stage hepatectomy or ALPPS for bilateral disease with small future liver remnant, Dr. Sun's expertise in these technically demanding procedures provides access to potentially curative resection that is available at only a small number of centers in China. The cost of hepatic surgery consultation and surgery at FUSCC is substantially below that of equivalent care in Western healthcare systems, and access to specialist consultation can typically be arranged within days through CMCS.
What to Expect at Your Consultation
Consultations with Dr. Sun Huichuan at FUSCC arranged through CMCS begin with a comprehensive review of all prior hepatic imaging — including multiphasic CT or MRI of the liver, chest CT, and PET-CT for staging — liver function tests, viral hepatitis serology and viral load, AFP and other tumor markers, prior pathology results, and prior treatment records including surgery, TACE, ablation, and systemic therapy. CMCS will arrange certified translation of all medical records and imaging reports in advance of the consultation. Dr. Sun will assess the tumor stage and hepatic functional reserve, evaluate surgical resectability and approach, outline the recommended treatment strategy — including the role and sequencing of surgery, downstaging therapy, and adjuvant treatment — and coordinate multidisciplinary tumor board review. A written English-language consultation summary is provided after every appointment, and CMCS will facilitate direct communication between Dr. Sun's team and the patient's home oncologist or surgeon for continuity of care planning.
Book a Consultation Through CMCS
China Medical Concierge Shanghai (CMCS) provides comprehensive end-to-end support for international patients seeking hepatic oncological surgery consultation with Dr. Sun Huichuan at Fudan University Shanghai Cancer Center. Our services include priority consultation scheduling, certified medical record and imaging report translation, coordination of additional hepatic imaging and liver function investigations, on-site interpretation, surgical logistics and hospital admission coordination, and written English-language reporting of all findings and recommendations.
📧 contract@medicalsh.com | 💬 WeChat: gezhanglao | 🌐 medicalsh.com
0 Kommentare